Article tools
Author information
Published in Volume 102, Issue 7 (October 1,1998)
J. Clin. Invest. 102(7): 1292-1300 (1998). doi:10.1172/JCI3880.
Copyright © 1998, The American Society for Clinical Investigation

Research Article

A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy.

Q Yang, A Sanbe, H Osinska, T E Hewett, R Klevitsky and J Robbins

Department of Pediatrics, Division of Molecular Cardiovascular Biology, Children's Hospital Research Foundation, Cincinnati, Ohio 45229-3039, USA.

Published October 1, 1998

Familial hypertrophic cardiomyopathy can be caused by mutations in genes encoding sarcomeric proteins, including the cardiac isoform of myosin binding protein C (MyBP-C), and multiple mutations which cause truncated forms of the protein to be made are linked to the disease. We have created transgenic mice in which varying amounts of a mutated MyBP-C, lacking the myosin and titin binding domains, are expressed in the heart. The transgenically encoded, truncated protein is stable but is not incorporated efficiently into the sarcomere. The transgenic muscle fibers showed a leftward shift in the pCa2+-force curve and, importantly, their power output was reduced. Additionally, expression of the mutant protein leads to decreased levels of endogenous MyBP-C, resulting in a striking pattern of sarcomere disorganization and dysgenesis.

This article Copyright © 1998, The American Society for Clinical Investigation.

Articles that cite this article:

FROM THE SARCOMERE TO THE NUCLEUS: Role of Genetics and Signaling in Structural Heart Disease
R. L. Nicol, N. Frey, E. N. Olson
Annu Rev Genom Human Genet 1(1):179. doi:10.1146/annurev.genom.1.1.179 [CrossRef]

Meeting Koch’s postulates for calcium signaling in cardiac hypertrophy
Kenneth R. Chien
J Clin Invest 105(10):1339. doi:10.1172/JCI10079 [CrossRef]

Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice
Bradley K. Mcconnell, Karen A. Jones, Diane Fatkin, Luis H. Arroyo, Richard T. Lee, Orlando Aristizabal, Daniel H. Turnbull, Dimitrios Georgakopoulos, David Kass, Meredith Bond
J Clin Invest 104(9):1235. doi:10.1172/JCI7377 [CrossRef]

A transgenic rabbit model for human hypertrophic cardiomyopathy
Ali J. Marian, Yun Wu, Do-Sun Lim, Meghan Mccluggage, Keith Youker, Qun-tao Yu, Ramon Brugada, Francesco Demayo, Miguel Quinones, Robert Roberts
J Clin Invest 104(12):1683. doi:10.1172/JCI7956 [CrossRef]

GENES, CALCIUM AND MODIFYING FACTORS IN HYPERTROPHIC CARDIOMYOPATHY
Tatiana Tsoutsman, Lien Lam, Christopher Semsarian
Clin Exp Pharmacol Physiol 33(1-2):139. doi:10.1111/j.1440-1681.2006.04340.x [CrossRef]

Sarcomeric Proteins and Familial Hypertrophic Cardiomyopathy: Linking Mutations in Structural Proteins to Complex Cardiovascular Phenotypes
Jil C. Tardiff
Heart Fail Rev 10(3):237. doi:10.1007/s10741-005-5253-5 [CrossRef]

Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease
Philippe Charron, Michel Komajda
Expert Rev Mol Diagn 6(1):65. doi:10.1586/14737159.6.1.65 [CrossRef]

Cardiac hypertrophy and failure: lessons learned from genetically engineered mice
Y. Takeishi, R. A. Walsh
Acta Physiol Scand 173(1):103. doi:10.1046/j.1365-201X.2001.00890.x [CrossRef]

A role for C-protein in the regulation of contraction and intracellular Ca2+ in intact rat ventricular myocytes
S. C. Calaghan, J. Trinick, P. J. Knight, E. White
J Physiol 528(1):151. doi:10.1111/j.1469-7793.2000.00151.x [CrossRef]

Molecular diagnosis of myocardial disease
Jeffrey A Towbin, Neil E Bowles
Expert Rev Mol Diagn 2(6):587. doi:10.1586/14737159.2.6.587 [CrossRef]

Disruption of myofibrillar proteins in cardiac muscle of Calomys callosus chronically infected with Trypanosoma cruzi and treated with immunosuppressive agent
Noemi N. Taniwaki, Walter K. Andreoli, Kátia S. Calabrese, Solange da Silva, Renato A. Mortara
Parasitol Res 97(4):323. doi:10.1007/s00436-005-1429-0 [CrossRef]

Hypertrophic cardiomyopathy: from gene defect to clinical disease
Man-Wei Chung, Tatiana Tsoutsman, Christopher Semsarian
Cell Res 13(1):9. doi:10.1038/sj.cr.7290146 [CrossRef]

Myosin binding protein C: Structural abnormalities in familial hypertrophic cardiomyopathy
Cecily E Oakley, Brett D Hambly, Paul MG Curmi, Louise J Brown
Cell Res 14(2):95. doi:10.1038/sj.cr.7290208 [CrossRef]

Sarcomeric proteins and inherited cardiomyopathies
S. Morimoto
Cardiovasc Res 77(4):659. doi:10.1093/cvr/cvm084 [CrossRef]

TGFβ inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway
Nalini M. Rajamannan, Malayannan Subramaniam, Theodore P. Abraham, Vlad C. Vasile, Michael J. Ackerman, David G. Monroe, Teng-Leong Chew, Thomas C. Spelsberg
J Cell Biochem 100(2):315. doi:10.1002/jcb.21049 [CrossRef]

Cardiac Electrophysiology in Genetically Engineered Mice
JOSEF Gehrmann, CHARLES I. Berul
J Cardiovasc Electrophysiol 11(3):354. doi:10.1111/j.1540-8167.2000.tb01806.x [CrossRef]

Molecular genetics of hypertrophic cardiomyopathy
Jeffrey A. Towbin
Curr Cardiol Rep 2(2):134. doi:10.1007/s11886-000-0010-9 [CrossRef]

Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics
RONNY Alcalai, JONATHAN G. Seidman, CHRISTINE E. Seidman
J Cardiovasc Electrophysiol 0(0):071004055652012. doi:10.1111/j.1540-8167.2007.00965.x [CrossRef]

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
F. Cambronero, F. Marin, V. Roldan, D. Hernandez-romero, M. Valdes, G. Y.H. Lip
Eur Heart J 30(2):139. doi:10.1093/eurheartj/ehn538 [CrossRef]

Build it up-Tear it down: protein quality control in the cardiac sarcomere
M. S. Willis, J. C. Schisler, A. L. Portbury, C. Patterson
Cardiovasc Res 81(3):439. doi:10.1093/cvr/cvn289 [CrossRef]